List of Figures
Figure 1: RA Therapeutics Market, Australia, Age-Specific Prevalence (%), 2014–2015 10
Figure 2: American College of Rheumatology Treatment Guidelines, 2015 15
Figure 3: European League Against Rheumatism Treatment Guidelines, 2016 16
Figure 4: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Conventional Synthetic Disease Modifying Anti-rheumatic Marketed Products 37
Figure 5: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Anti TNF-a Biologic Disease Modifying Anti-rheumatic Marketed Products 39
Figure 6: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Non-TNF-a Biologic Disease Modifying Anti-rheumatic Marketed Products 40
Figure 7: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Targeted Synthetic Disease Modifying Anti-rheumatic Marketed Products 41
Figure 8: RA Therapeutics Market, Global, Pipeline, 2016 44
Figure 9 RA Therapeutics Market, Global, Pipeline by Molecular Target, 2016 47
Figure 10: RA Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 48
Figure 11: RA Therapeutics Market, APAC, Sirukumab Forecast ($m), 2018–2023 50
Figure 12: RA Therapeutics Market, APAC, Peficitinib Forecast ($m), 2019–2023 52
Figure 13: RA Therapeutics Market, APAC, Upadacitinib Forecast ($m), 2022–2023 55
Figure 14: RA Therapeutics Market, APAC, Filgotinib Forecast ($m), 2020–2023 57
Figure 15: RA Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products 60
Figure 16: RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2017 62
Figure 17: RA Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2016 64
Figure 18: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006–2016 65
Figure 19: RA Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006–2016 66
Figure 20: RA Therapeutics Market, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006–2016 67
Figure 21: RA Therapeutics Market, Global, Clinical Trial Duration by Molecular Target, 2006–2016 68
Figure 22: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2006–2016 69
Figure 23: RA Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2006–2016 70
Figure 24: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Type, 2006–2016 71
Figure 25: RA Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target, 2006–2016 72
Figure 26: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type 72
Figure 27: RA Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target 73
Figure 28: RA Therapeutics Market, Asia Pacific, Treatment Usage Patterns (million), 2016–2023 75
Figure 29: RA Therapeutics Market, Asia Pacific, Market Size ($bn), 2016–2023 76
Figure 30: RA Therapeutics Market, India, Treatment Usage Patterns (’000), 2016–2023 77
Figure 31: RA Therapeutics Market, India, Annual Cost of Therapy ($), 2016–2023 78
Figure 32: RA Therapeutics Market, India, Market Size ($m), 2016–2023 79
Figure 33: RA Therapeutics Market, China, Treatment Usage Patterns (‘000), 2016–2023 80
Figure 34: RA Therapeutics Market, China, Annual Cost of Therapy ($), 2016–2023 81
Figure 35: RA Therapeutics Market, China, Market Size ($m), 2016–2023 82
Figure 36: RA Therapeutics Market, Australia, Treatment Usage Patterns (‘000), 2016–2023 83
Figure 37: RA Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016–2023 84
Figure 38: RA Therapeutics Market, Australia, Market Size ($m), 2016–2023 85
Figure 39: RA Therapeutics Market, South Korea, Treatment Usage Patterns (‘000), 2016–2023 86
Figure 40: RA Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023 87
Figure 41: RA Therapeutics Market, South Korea, Market Size ($m), 2016–2023 88
Figure 42: RA Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2016–2023 89
Figure 43: RA Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016–2023 90
Figure 44: RA Therapeutics Market, Japan, Market Size ($m), 2016–2023 91
Figure 45: RA Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2017 95
Figure 46: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017 96
Figure 47: RA Therapeutics Market, Global, Licensing Deals by Stage of Development, and Deal Value, 2006–2017 97
Figure 48: RA Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2017 98
Figure 49: RA Therapeutics Market, Global, Licensing Deals by Molecular Target and Aggregate Deal Value ($m), 2006–2017 99
Figure 50: RA Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006–2017 104
Figure 51: RA Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017 105
Figure 52: RA Therapeutics Market, Global, Co-development Deals by Stage of Development, and Deal Value, 2006–2016 106
Figure 53: RA Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2006–2017 107
Figure 54: Rheumatoid Arthritis Market, Global, Co-development Deals by Molecular Target, 2006–2017 108